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esponsibility of InstAbstract Kallistatin, which protects organs and cells against inﬂammation, ﬁbrosis and oxidative stress,
is mainly synthesized and secreted in liver. However, its relationship to human liver disease remains
unclear. The purpose of this study was to explore the relationship between serum kallistatin and clinical
evidence of both cirrhosis and hepatocellular carcinoma (HCC), and to determine if serum kallistatin
levels could be used as a diagnostic indicator of hepatic health status, especially human liver cirrhosis
(LC). Our cohort consisted of 115 patients with clinically proven liver ﬁbrosis (LF), LC, or HCC by liver
biopsies, and 31 healthy controls (CON). Serum kallistatin levels were quantiﬁed by ELISA. Results of
the present study demonstrated that irrespective of the underlying etiology, serum kallistatin levels were
signiﬁcantly lower in the LF/LC group when compared with the CON group. A decrease in serum
kallistatin levels appeared to reﬂect the extent of cirrhosis, with the lowest levels associated with higher
grades of cirrhosis. Patients with LC had a noticeable correlation between serum kallistatin levels and
other serum biochemical indicators. The area under the curve (AUC) for LC, viral liver cirrhosis (VLC)
and alcoholic liver cirrhosis (ALC) was 0.845, 0.757 and 0.931, respectively. In conclusion, our ﬁndings3
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Kallistatin, a new and reliable biomarker 195demonstrated that kallistatin, a plasma protein produced by the liver, can be a useful and reliable
diagnostic indicator of hepatic health status, especially for LC.
& 2015 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical
Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Liver cirrhosis (LC), characterized by the histological development
of regenerative nodules surrounded by ﬁbrous bands, is the most
frequent long term consequence of all chronic liver diseases.
Cirrhosis is often asymptomatic and unsuspected until complica-
tions emerge (e.g. liver failure, portal hypertension, ascites, hepatic
encephalopathy, variceal hemorrhage, hepatocellular carcinoma
(HCC)). The annual incidence rates of liver failure (decompensa-
tion), HCC, and death in patients with cirrhosis associated with
chronic hepatitis B or C infection are approximately 4%, 3% and
3%, respectively1. The majority of patients with LC die from life-
threatening complications, which occurred relatively early in the
course of the disease. Thus, the early diagnosis of LC is important
for patients with chronic liver disease.
The deﬁnitive diagnosis of cirrhosis relies on the histological
examination of liver tissue. The use of liver biopsies in clinical
practice, however, has several limitations. In particular, sample errors
are a signiﬁcant problem, with an estimated mean of 24% of false
negatives being reported in series of blind liver biopsies2. Therefore
routine clinical investigation of liver function employs serum analysis
of indicators of liver dysfunction, such as increases in alanine
transaminase (ALT) and aspartate aminotransferase (AST) amongst
others. The complexity of LC and the inﬂuence of a multitude of
genetic and environmental factors on the course of disease progression
and response to therapy suggest the need to extend the battery of
serum based functional assays that could add to the sensitivity and
accuracy of currently employed diagnostic and prognostic markers.
Kallistatin, a tissue-kallikrein, has vasodilatory, anti-angiogenic,
anti-inﬂammatory, anti-tumor and anti-oxidant effects3–6. It is present
in many human tissues, including the eye, kidney, liver, heart, arteries
and veins, atheroma, blood cells and body ﬂuids7,8. As several studies
have shown that the liver represents the major site of synthesis and
secretion of kallistatin7,9, we therefore hypothesized that serum
kallistatin levels could be a potential biomarker for liver cirrhosis.
We have explored the relationship between serum kallistatin and
clinical evidence of both human cirrhosis and HCC in this study.2. Participants and methods
2.1. Participants
Serum samples were collected at the Fujian Strait Hospital from 12
patients with LF, 93 with LC and 10 with HCC (without LC)
proven by liver biopsies (Figs. S1 and S2 in Supporting
information). LC patients had diverse etiologies: 41 patients were
diagnosed with hepatitis B or C virus infection, 7 with alcoholic
liver cirrhosis (ALC), and 45 had liver cirrhosis of uncertain cause.
Eighteen of the patients with viral liver cirrhosis (VLC) (the cause
of LC came from HBV infection) received different anti-cirrhotic
drugs (Lamivudine, Sebivo or Adefovir dipivoxil, respectively)and had their serum samples re-collected 30 days after the
treatment. Thirty healthy volunteers served as controls. The study
was approved by the local ethics committee (Quanzhou, No.
201001) and written informed consent was obtained from all
patients involved.
2.2. Serum separation
Serum was collected from clotted blood using serum separator
tubes centrifuged at 4000 rpm for 10 min at 4 1C. The serum was
snap-frozen and stored at 80 1C until required. All serum
samples were thawed only once.
2.3. Determination of serum kallistatin
Kallistatin levels were quantiﬁed by ELISA (R&D Systems, Inc.
Minneapolis, USA) as previously described10. Brieﬂy, standards
and clinical samples were added in duplicate at appropriate
dilutions into 96-well microtiter plate coated with capture
antibodies.
2.4. Determination of other serum biochemical indicators
The clinical serum samples were also used to measure: serum
prealbumin (PA), serum total protein (STP), albumin (ALB),
albumin/globulin ratio (ALB/GLB), choline esterase (CE), globu-
lin (GLB), total bilirubin (TBIL), direct bilirubin (DBIL), indirect
bilirubin (IBIL), ALT, AST, gamma-glutamyl transpeptidase
(GGT), alkaline phosphatase (ALP) and total bile acid (TBA).
All of the parameters were measured using a conventional
automated analyzer (Beckman Au680).
2.5. Statistical analysis
Data were expressed as mean7SD. All statistical analyses were
performed using SPSS 16.0 software. The t-test was used for
univariate comparisons between patients and the CON group with
Po0.05 considered signiﬁcant. The Pearson correlation test,
Spearman's rank correlation test and Logistic regression analysis
were used to determine associations between variables. Receiver
operating characteristic (ROC) curve analyses were performed to
determine the diagnostic sensitivity and speciﬁcity of parameters.
The area under the ROC curve (AUC) was calculated for
prediction of patients with LC and the best cut-off values were
established for the serum kallistatin levels.3. Results
3.1. The main features and laboratory characteristics of all
subjects
The serum levels of liver function tests, including PA, STP, ALB,
GLB, ALT, AST, TBLI, DBIL, IBIL, GGT, ALP and TBA in the
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L)3.2. Serum kallistatin levels in patients with LF/LC
Serum kallistatin levels were signiﬁcantly lower in the 12 LF
patients and 93 LC patients as compared to the CON groups (LF
22.7775.02 & LC 16.7878.65 vs. CON 29.0378.07 μg/mL;
Po0.05, Po0.01) (Fig. 1). This trend did not appear to be
inﬂuenced by etiology: whether the cause of LC was viral
infection or excessive alcohol consumption, the serum levels of
kallistatin were signiﬁcantly lower than the CON (VLC
19.8479.71 & ALC 16.3873.82 vs. CON 29.0378.07 μg/mL;
Po0.01). Kallistatin levels were similar for the VLC and ALC
groups. In addition, various age or sex groups had no signiﬁcant
differences in serum kallistatin levels (data not shown).
Comparison of the LF and LC groups showed that serum
kallistatin levels were further decreased (Po0.05) (Fig. 1).
Analysis of kallistatin levels in patients with different severities
of LC revealed higher serum kallistatin concentrations in patients
with compensated LC compared to patients with decompensated
LC (19.98710.14 vs. 12.2576.22 μg/mL; Po0.05), suggesting
that serum levels of kallistatin may reﬂect the degree of liver
dysfunction.
A follow-up study of 18 patients with VLC who received the
anti-cirrhotic treatment (Lamivudine, Sebivo or Adefovir dipivoxil
respectively) for 30 days showed elevated kallistatin levels after
the treatment (13.6777.81 prior to vs. 17.0976.89 mg/mL follow-
ing the treatment).CON LF LC HCC
0
S
Group
Figure 1 Mean concentration of serum kallistatin in the patients
with LF, LC and HCC. Kallistatin levels were signiﬁcantly different
between LF, LC, HCC and controls (*Po0.05, **Po0.01).3.3. Serum kallistatin levels in patients with HCC
HCC groups had lower serum kallistatin levels than CON groups
(25.0577.20 vs. 29.0378.06 μg/mL), but higher than the LC
groups (Po0.05) (Fig. 1). These results suggest that decreases inTable 1 Demographic and clinical characteristics of the study popu
CON LF
Parameter (n¼31) (n¼12
Age (years) 35.10710.40 41.587
Gender (male; female) 8;23 9
Kallistatin (μg/mL) 29.0378.07 22.777
Prealbumin (g/L) 74.2973.18 24.897
STP (g/L) 43.6772.24 71.717
Albumin (g/L) 30.0573.13 44.467
Globulin (g/L) 21.5472.82 27.257
Albumin/Globulin 1.4570.12 1.677
ALT (U/L) 24.81714.21 99.897
AST (U/L) 18.8775.49 48.767
AST/ALT 0.9370.43 0.777
Choline esterase (KU/L) 8.3872.2 8.197
Total bilirubin (μmol/L) 13.8675.45 15.907
Direct bilirubin (μmol/L) 5.0372.17 4.097
Indirect bilirubin (μmol/L) 10.3476.82 11.817
GGT (U/L) 25.13713.84 1607
ALP (U/L) 90.42732.71 121.507
TBA (μmol/L) 6.1373.85 7.967serum kallistatin levels are not unique to patients with LC, but may
reﬂect different etiologies of liver disease.3.4. Relationship between kallistatin serum levels and liver
function
Patients with LC had a noticeable positive correlation between
serum kallistatin levels and serum PA, STP, ALB, ALB/GLB and
CE. Also, they had a signiﬁcantly negative correlation between
serum kallistatin levels and TBIL, ALT and AST levels, as
determined by Pearson and Spearman rank correlation tests
(Table 2) and linear regression analysis (Fig. 2).
Table 3 presents the association of each characteristic (serum
kallistatin levels and other biochemical indicators) with LC
(unadjusted odds ratios). It seemed that all the variables exceptlation with LF, LC and HCC.
LC HCC
) (n¼93) (n¼10)
12.75 52.29711.98 59.40710.84
;3 77;16 7;3
5.02 16.7878.65 25.0577.20
5.89 11.6775.49 14.5875.61
6.28 67.3379.92 70.0076.74
3.37 33.5277.18 37.7575.40
4.96 33.8078.02 32.2574.81
0.27 1.0570.33 1.2070.29
146.17 48.97769.74 98.767156.35
44.62 64.277120.38 76.76794.59
0.34 1.3470.52 1.0870.57
1.94 6.3873.22 8.1474.03
5.65 48.64763.13 32.76748.84
2.07 20.95734.73 16.29726.34
3.99 27.36731.37 21.01721.58
424.66 71.44783.45 169.337284.42
169.57 135.10770.82 307.907355.98
6.6 57.85773.64 34.63749.82
Kallistatin, a new and reliable biomarker 197PA and STP were signiﬁcantly associated with liver cirrhosis. But
only ALB and GLB were included in the ﬁnal model, which was
determined by performing multivariate logistic regression with
stepwise selection of LC, and signiﬁcant variables at level of 0.05.
It was indicated from the ﬁnal model that for 1 μg/mL increase in
serum kallistatin concentration, the odds of liver cirrhosis
decreases by (10.682) 100%¼31.8% after controlling the
effect of all the other covariates.3.5. Reliability of serum kallistatin level as predictor of LC
The serum kallistatin level predicted the presence of LC estimated with
AUC of 0.845 in 93 patients (Fig. 3A). Based on the ROC curve, an
optimal cut-off value for LC diagnosis was set o21.64 μg/mL of
kallistatin. Sensitivity (Se), speciﬁcity (Sp), positive predictive value
(PPV) and negative predictive value (NPV) values were 87.1%, 74.2%,
91% and 62.3%, respectively (Table S1 in supporting information).Table 2 Pearson correlation (r-value) and spearman rank correlation
concentration in all cirrhotic patients without HCC.
Pearson correlation
Parameter r P
Prealbumin (g/L) 0.699 o0
STP (g/L) 0.523 o0
Albumin (g/L) 0.313 0
ALB/GLB 0.372 o0
Choline esterase (U/L) 0.699 o0
ALT (U/L)
AST (U/L)
Total bilirubin (μmol/L)
Direct bilirubin (μmol/L)
Indirect bilirubin (μmol/L)
TBA (μmol/L)
Figure 2 Correlation between serum kallistatin levels and other biomarke
levels in μg/mL and the horizontal axis represents the expression levels o3.6. Receiver operating characteristic curves for predicting VLC
and ALC
In the cases of discriminating VLC and ALC from the CON patients
based on the kallistatin level, the AUCs were 0.757 (P¼0.001) and
0.931 (Po0.01) respectively. The results indicate that the predictive
value is signiﬁcantly better for patients with ALC than for the ones
with VLC (Fig. 3B, C and Table S1 in Supporting information).3.7. Disease speciﬁcity for LC
Using similar ROC analyses, we found that kallistatin level was
not a reliable predictor of HCC, even though the levels in those
patients were lower than in the CON groups. Serum kallistatin is
therefore a good biomarker for different etiologies of LC with
exception of HCC.(ρ) between biochemical indices of liver sufﬁciency and kallistatin
Spearman rank correlation
ρ P
.001 0.671 o0.001
.001 0.536 0.005
.002 0.326 o0.001
.001 0.392 o0.001
.001 0.645 o0.001
0.224 0.031
0.348 0.001
0.313 0.002
0.329 0.001
0.288 0.005
0.257 0.013
rs in 93 patients with LC. The vertical axis represents serum kallistatin
f serum PA, STP, ALB, ALB/GLB and CE.
Table 3 Logistic regression analysis of liver cirrhosis.
Variable Unadjusted Unadjusted OR Final model
95% CI P-value Unadjusted OR 95% CI P-value
PA 0.72 0.325–1.594 0.4172
STP 1.00 0.993–1.007 0.9254
ALB 1.09 1.019–1.174 0.0133 1.36 1.072–1.716 0.01
GLB 1.73 1.387–2.159 o0.0001 1.95 1.272–2.990 0.00
ALB/GLB 0.00 o0.001–0.033 o0.0001
CE 1.00 1.0001–1.0008 0.0027
ALT 1.04 1.008–1.071 0.0122
AST 1.22 1.121–1.328 o0.0001
AST/ALT 9.82 2.777–34.723 0.0004
TBIL 1.22 1.114–1.334 o0.0001
DBIL 1.46 1.178–1.815 0.0006
IBIL 1.19 1.092–1.298 o0.0001
GGT 1.04 1.012–1.063 0.0037
ALP 1.02 1.008–1.035 0.0015
TBA 1.19 1.080–1.319 0.0005
Figure 3 Serum kallstatin levels can accurately diagnose liver disease. A: LC; B: VLC; C: ALC. The AUC is shown for the performance of the
serum kallistatin levels for discriminating LC, VLC and ALC from the healthy control groups. The vertical axis represents the sensitivity and the
horizontal axis represents the 1-speciﬁcity.
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To our knowledge, the present study is the ﬁrst to demonstrate
kallistatin to be a useful potential biomarker for the detection of
human LC. The data presented in this study showed that serum
kallistatin levels in patients with LC were signiﬁcantly lower than
those in healthy controls, demonstrating a close correlation
between the reduction in serum kallistatin levels and severity of
early hepatic disease. Serum kallistatin levels could therefore
provide an additional biomarker for the detection of LC and
progressive loss of liver function along in response to the therapy.
The biology of LC is characterized by a constant stimulus for
hepatocellular regeneration by a microenvironment associated with
chronic inﬂammation and tissue ﬁbrosis. Cirrhosis represents the
ﬁnal common pathological outcome for the majority of chronic
liver diseases. Previous studies have shown that 30%-40% of non-
alcoholic steatohepatitis (NASH) patients have advancing bridging
ﬁbrosis or cirrhosis11–13. Most patients with cirrhosis die from one
or more clinical complications including ascites, hepatic encepha-
lopathy and variceal hemorrhage14. Among the 1.4 million liver-
disease-related deaths that occur each year worldwide, over 55%,
or 796,000, are directly attributable to cirrhosis15.Liver transplantation has been the most effective therapy for
patients with many types of advanced liver disease. Unfortunately,
many patients cannot obtain transplantation due to the limited
availability of donor livers, with over 10% of patients dying whilst
on the waiting list. Of those patients who receive liver transplants,
94% survive after three months, 88% after one year and 79% after
three years16. Furthermore, evidence of either ﬁbrotic or cirrhotic
regression has now been reported in chronic liver diseases of
different etiologies, including viral hepatitis17–24, autoimmune
hepatitis25, alcoholic and NASH26,27. While traditionally consid-
ered irreversible, recent evidence from animal studies and human
clinical observations indicated that even advanced ﬁbrosis can be
reversed17,28. This makes it important to identify reliable biomar-
kers for the early detection of liver disease and subsequent
evaluation of response to therapeutic intervention. The ability of
serum biomarkers of liver function to further discriminate between
LC and HCC would add a major advantage.
Since ﬁrst identiﬁed as a tissue kallikrein-binding protein
(KBP), kallistatin mRNA was found in varying amounts in
human liver, stomach, pancreas, kidney, aorta, testes, prostate,
artery, atrium, ventricle and lung29. By far, the most important
site of synthesis of kallistatin is the liver30, explaining the
Kallistatin, a new and reliable biomarker 199signiﬁcantly reduced levels of serum kallistatin in patients
with LC.
Kallistatin can inhibit tumor growth5, reduce blood pressure31,
suppress arthritis6,32 and protect organs and cells against inﬂam-
mation, ﬁbrosis, and oxidative stress33–35. The anti-oxidative effect
of kallistatin can also inhibit salt-induced renal injury, inﬂamma-
tion, and ﬁbrosis34.
The patients with HCC had lower serum kallistatin levels than
normal controls, but signiﬁcantly higher than in patients with LC.
Thus, an inverse relationship between oxidative stress and
kallistatin level might exist. This would be consistent with data
demonstrating that male Sprague-Dawley (SD) rats exposed to
either episodic or sustained hypoxia have reduced renal expression
of kallistatin36. Moreover, chronic oxidative organ damage can
markedly reduce circulating kallistatin levels in rats, while hydro-
gen peroxide (H2O2) lowers kallistatin mRNA and protein levels
in dose-dependent fashion in vitro33. Kallistatin is known to play
an important role in prevention of cancer, probably through its
anti-angiogenic effects5. The human body can therefore up-
regulate kallistatin expression when cancers occur in a self-
protective mechanism. In agreement with data in our present
study, previous examination of plasma kallistatin concentrations
detected 22.173.5 mg/mL in 30 normal subjects and
21.173.8 mg/mL in ﬁve patients with hereditary angioedema7. A
signiﬁcant decrease in kallistatin levels (7.272.5 mg/mL,
Po0.001) was also found in plasma samples from nine patients
with liver disease7. Such a discrepancy may be related to
differences in the populations studied or may reﬂect the relatively
small sample size. We have previously demonstrated that trans-
genic expression of kallistatin can signiﬁcantly attenuate carbon
tetrachloride-induced liver damage37. This anti-inﬂammatory, anti-
ﬁbrotic potential of kallistatin warrants clinical evaluation, either
with gene-therapy-based or recombinant-protein-administration-
based evaluation of its therapeutic potential in human LC.
Previous studies showed that other clinical situations can also
affect serum kallistatin levels, such as adiposity, community-
acquired pneumonia (CAP) and type 1 diabetes38,39. Serum
kallistatin levels were signiﬁcantly increased in diabetic vs. non-
diabetic control subjects (12.674.2 vs. 10.372.8 μg/mL), and
showing that levels were higher in diabetic patients with compli-
cations but did not differ for complication-free patients38. A study
of CAP assessing the correlations of kallistatin with other
biomarkers found that kallistatin was signiﬁcantly consumed in
CAP patients (median: 8.3, range 1.3–17.3 μg/mL) compared with
healthy subjects (median: 17.2, range 5.3-82.7 μg/mL)39. These
studies emphasize the diagnostic value of serum kallistatin levels
in human LC, even though CAP patients have lower serum
kallistatin levels, and the downgrading is fairly modest. However,
the levels were decreased in liver disease but increased in diabetic
patients. Therefore, comprehensive evaluation of kallistatin level
and patients with obesity and diabetes history may determine their
liver health more accurately.
In conclusion, the present study demonstrated the levels of
serum kallistatin reduced signiﬁcantly in patients with LC of
different etiologies, but not with HCC. The magnitude of this
decrease appeared to be correlated with the degree of LC and
disruption of normal liver function. Kallistatin therefore has a
potential as a new biomarker for the diagnosis of, and evaluation
of the extent of human LC, along with its response to therapeutic
intervention. Furthermore, kallistatin may provide a new thera-
peutic strategy for the management and treatment of cirrhotic liver
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